Roth MKM Reiterates Buy on ASLAN Pharma, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
Roth MKM analyst Dylan Dupuis has reiterated a 'Buy' rating on ASLAN Pharma (NASDAQ:ASLN) and maintained a price target of $15.
August 14, 2023 | 1:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ASLAN Pharma's stock rating has been reiterated as 'Buy' by Roth MKM analyst Dylan Dupuis, with a maintained price target of $15.
The reiteration of a 'Buy' rating and maintenance of a $15 price target by a Roth MKM analyst indicates strong confidence in ASLAN Pharma's stock. This could potentially lead to increased investor interest and a positive impact on the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100